Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B.

Mechanistic and structural studies have been carried out to investigate the molecular basis for the irreversible inhibition of human MAO-B by mofegiline. Competitive inhibition with substrate shows an apparent K(i) of 28 nM. Irreversible inhibition of MAO-B occurs with a 1:1 molar stoichiometry with no observable catalytic turnover. The absorption spectral properties of mofegiline inhibited MAO-B show features (lambda(max) approximately 450 nm) unlike those of traditional flavin N(5) or C(4a) adducts. Visible and near-UV circular dichroism spectra of the mofegiline-MAO-B adduct shows a negative peak at 340 nm with an intensity similar to that of N(5) flavocyanine adducts. The X-ray crystal structure of the mofegiline-MAO-B adduct shows a covalent bond between the flavin cofactor N(5) with the distal allylamine carbon atom as well as the absence of the fluorine atom. A mechanism to explain these structural and spectral data is proposed.

[1]  A. Mattevi,et al.  Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B. , 2008, Biochemistry.

[2]  J. Shih,et al.  Monoamine oxidase: from genes to behavior. , 1999, Annual review of neuroscience.

[3]  R. Rando,et al.  The pseudoirreversible inhibition of monoamine oxidase by allylamine. , 1977, Molecular pharmacology.

[4]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[5]  C. Olanow.  Rationale for considering that propargylamines might be neuroprotective in Parkinson’s disease , 2006, Neurology.

[6]  D. Edmondson,et al.  High-level expression of human liver monoamine oxidase B in Pichia pastoris. , 2000, Protein expression and purification.

[7]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[8]  M. Palfreyman,et al.  Dual enzyme-activated irreversible inhibition of monoamine oxidase , 1986 .

[9]  M. Palfreyman,et al.  Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential. , 1994, Journal of neural transmission. Supplementum.

[10]  C. Walsh,et al.  Overexpression, purification, and mechanistic study of UDP-N-acetylenolpyruvylglucosamine reductase. , 1993, Biochemistry.

[11]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[12]  C. Walsh,et al.  Kinetic characterization of wild-type and S229A mutant MurB: evidence for the role of Ser 229 as a general acid. , 1997, Biochemistry.

[13]  D. Edmondson,et al.  Structure-activity relations in the oxidation of phenethylamine analogues by recombinant human liver monoamine oxidase A. , 2000, Biochemistry.

[14]  Andrea Mattevi,et al.  Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  N. Volkow,et al.  Age-Related Increases in Brain Monoamine Oxidase B in Living Healthy Human Subjects , 1997, Neurobiology of Aging.

[16]  M. Youdim,et al.  Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. , 2004, Journal of medicinal chemistry.

[17]  C. Poulter,et al.  Type II isopentenyl diphosphate isomerase: irreversible inactivation by covalent modification of flavin. , 2008, Journal of the American Chemical Society.

[18]  Andrea Mattevi,et al.  Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders , 2002, Nature Structural Biology.

[19]  A G Leslie,et al.  Biological Crystallography Integration of Macromolecular Diffraction Data , 2022 .

[20]  A. Sjoerdsma,et al.  Design and early clinical evaluation of selective inhibitors of monoamine oxidase , 1988, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  P. Hemmerich,et al.  The chemical and electronic structure of the neutral flavin radical as revealed by electron spin resonance spectroscopy of chemically and isotopically substituted derivatives. , 1970, European journal of biochemistry.

[22]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[23]  R. Silverman,et al.  Inactivation of monoamine oxidase by allylamine does not result in flavin attachment. , 1985, The Journal of biological chemistry.

[24]  W Poewe,et al.  Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial , 2005, The Lancet.

[25]  P. Seeburg,et al.  cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Edmondson,et al.  High-level expression of human liver monoamine oxidase A in Pichia pastoris: comparison with the enzyme expressed in Saccharomyces cerevisiae. , 2002, Protein expression and purification.

[27]  N. Panchuk-Voloshina,et al.  A one-step fluorometric method for the continuous measurement of monoamine oxidase activity. , 1997, Analytical biochemistry.

[28]  R M Esnouf,et al.  Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. , 1999, Acta crystallographica. Section D, Biological crystallography.

[29]  X. Breakefield,et al.  Biochemistry and genetics of monoamine oxidase. , 1990, Pharmacology & therapeutics.

[30]  A. Mattevi,et al.  Functional role of the "aromatic cage" in human monoamine oxidase B: structures and catalytic properties of Tyr435 mutant proteins. , 2006, Biochemistry.

[31]  E. Billett,et al.  Cellular localization of monoamine oxidase A and B in human tissues outside of the central nervous system , 2001, Cell and Tissue Research.